Evidence-Based Treatment of a Patient with Malignant Thymoma

Cao De-dong,Ge Wei,Wang Hui-min

DOI: https://doi.org/10.3969/j.issn.1009-0959.2010.11.047

2010-01-01

Abstract:Objective: he objective of this study is to find evidence-based treatment for a patient with malignant thymoma and superior vena cava syndrome(SVCS). Methods:Based on the PICO(patient intervention comparison outcome) principle and the clinical question raised, evidence was collected and critically assessed. We searched NGC,Cochrane Library,PubMed,Embase Database,SUM search,CBM,et al, for evidence. Results: There are 10 randomized controlled trials, 3 systematic reviews or meta-analyses and 1 clinical guideline included. Treatment plan was formed after we analyzed these data carefully. The evidence indicated that surgical operation is the preferred method in the treatment of malignant thymoma, and the tumor must be resected completely or as much as possible. For unresectable patients, induced chemoradiotherapy followed by surgery is a good choice. Platinum-based chemotherapy is one of the standard chemotherapies of malignant thymoma. In this case, we used preoperative cisplatin combined with docetaxel therapy three days for a few cycles and the preoperative radiation dose was 38Gy/19f, after the tumor volume reduced more than a half, the patient received surgery. This patient's outcome is PR after the above treatments, and enjoys a higher quality of life.Conclusion:The patients with temporarily unresectable malignant thymoma and SVCS might benefit from induced chemoradiotherapy and have a chance for resection. The short-term prognostic benefits is obvious, however the long-term prognostic benefits should be confirmed by further follow-up.